Lipid-lowering Agent Market, Global Outlook and Forecast 2023-2028

Report ID: 1139675 | Published Date: Jan 2025 | No. of Page: 117 | Base Year: 2024 | Rating: 4.3 | Webstory: Check our Web story

This report contains market size and forecasts of Lipid-lowering Agent in global, including the following market information:
Global Lipid-lowering Agent Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Lipid-lowering Agent Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Lipid-lowering Agent companies in 2021 (%)
The global Lipid-lowering Agent market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Niaci Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Lipid-lowering Agent include Pfizer, Merck, Teva, Amgen, Abbott, AstraZeneca, Novartis, SUN Pharma and Torrent Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Lipid-lowering Agent manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lipid-lowering Agent Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Lipid-lowering Agent Market Segment Percentages, by Type, 2021 (%)
Niaci
Acipimox
Fibrates
Others
Global Lipid-lowering Agent Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Lipid-lowering Agent Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Lipid-lowering Agent Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Lipid-lowering Agent Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Lipid-lowering Agent revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Lipid-lowering Agent revenues share in global market, 2021 (%)
Key companies Lipid-lowering Agent sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Lipid-lowering Agent sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Merck
Teva
Amgen
Abbott
AstraZeneca
Novartis
SUN Pharma
Torrent Pharmaceuticals
GlaxoSmithKline
HanAll BioPharma
JX Pharmaceuticals
Aurobindo Pharma
Abbvie
Cerenis Therapeutics

Frequently Asked Questions
Lipid-lowering Agent Market In Global report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Lipid-lowering Agent Market In Global report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Lipid-lowering Agent Market In Global report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports